Letrozole Tablet, Film Coated
Product Images NDC 63629-7819

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Letrozole (NDC 63629-7819). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl636297819)

Label for Letrozole 2.5 mg tablet, film-coated, oral dosage form, packaged by Bryant Ranch Prepack in Burbank, CA. The label includes storage instructions to keep at room temperature (20°-25°C) and a warning to keep all drugs out of reach of children. It compares Letrozole to Femara 2.5 mg tablets by Intas Pharmaceuticals Limited. The package contains 30 tablets and displays NDC 63629-7819.*

FDA Label Image

Figure 1 Disease-free Survival (median Follow-up 73 Months, Itt Approach) (Letrozole Fig1)

A Kaplan-Meier survival curve comparing treatment groups for Letrozole and Tamoxifen over 72 months. The graph shows the proportion of patients surviving without events over time with Letrozole represented by a solid line and Tamoxifen by a dashed line. Below the graph, the number of patients at risk for each treatment is listed at varying month intervals.*

FDA Label Image

Figure 2 Kaplan-meier Estimates Of Time To Progression (tamoxifen Study) (Letrozole Fig2)

A Kaplan-Meier plot showing progression-free survival over a 60-month period. The graph compares two treatments: Letrozole tablets 2.5 mg and tamoxifen 20 mg, with progression-free proportions plotted against time in months.*

FDA Label Image

Figure 3 Survival By Randomized Treatment Arm (Letrozole Fig3)

A survival curve graph comparing the percentage of patients alive over time in months for Letrozole and Tamoxifen treatments. The x-axis shows months from 0 to 60, and the y-axes on both left and right show the proportion alive from 0.0 to 1.0. The solid line represents Letrozole, and the dashed line represents Tamoxifen.*

FDA Label Image

Figure 4 Kaplan-meier Estimates Of Time To Progression (megestrol Acetate Study) (Letrozole Fig4)

A Kaplan-Meier survival curve chart showing time to progression in days on the x-axis and probability on the y-axis for treatment groups of Letrozole tablets at 0.5 mg and 2.5 mg dosages compared with MA (megestrol acetate). The graph compares progression rates across the three groups over time.*

FDA Label Image

Figure 5 Kaplan-meier Estimates Of Time To Progression (aminoglutethimide Study) (Letrozole Fig5)

A Kaplan-Meier curve graph depicting time to progression in days for different treatment groups. The graph compares Letrozole tablet treatments at 0.5 mg and 2.5 mg doses, as well as an additional treatment group labeled AG, illustrating their respective survival probabilities over time.*

FDA Label Image

Letrozole Structural Formula (Letrozole Str)

Chemical structure of letrozole, the active ingredient in the Letrozole 2.5 mg oral film-coated tablet by Bryant Ranch Prepack. The structure shows the molecular arrangement with two cyano-substituted phenyl rings connected to a triazole ring.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.